Results 41 to 50 of about 408 (149)
Black Phosphorus, an Emerging Versatile Nanoplatform for Cancer Immunotherapy
Pharmaceutics, 2021 Black phosphorus (BP) is one of the emerging versatile nanomaterials with outstanding biocompatibility and biodegradability, exhibiting great potential as a promising inorganic nanomaterial in the biomedical field.
Hao Liu +6 more
doaj +1 more source
Advances in Cancer Immunotherapy for Solid Tumors
Advanced Science, Volume 13, Issue 35, 24 June 2026.Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz +1 more
wiley +1 more source
Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6 [PDF]
, 2017 There is an increasing biotechnological interest in ‘arming' therapeutic antibodies with bioactive payloads. Many antibody-cytokine fusion proteins (immunocytokines) have been described and some of these biopharmaceuticals have progressed to clinical ...
Hess, Christian, Neri, Dario
core
Anti-CD70-IFN-γ immunocytokines induce species-specific phosphorylation of STAT1.
, 2013 Murine (RenCa) or human (Caki-1) RCC cells were treated with anti-CD70 immunocytokines bearing either murine (m) or human (h) IFN-γ (‘Anti-CD70 fusion’, 50 ng/ml).
Peirong Chen (403320) +7 more
core +1 more source
Scientific Reports, 2021 Type I Interferon (IFN) was the very first drug approved for the treatment of Multiple Sclerosis (MS), and is still frequently used as a first line therapy. However, systemic IFN also causes considerable side effects, affecting therapy adherence and dose
Anje Cauwels +9 more
doaj +1 more source
Immunocytokines : a review of molecules in clinical development for cancer
, 2013 The concept of therapeutically enhancing the immune system's responsiveness to tumors is long standing. Several cytokines have been investigated in clinical trials for their therapeutic activity in cancer patients.
Neri, Dario, +6 more
core +1 more source
Biopharmaceuticals for Cancer Treatment: An Update
Cancer Medicine, Volume 15, Issue 4, April 2026.ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath +6 more
wiley +1 more source
Echinacea purpurea Alleviates Cyclophosphamide-Induced Immunosuppression in Mice
Applied Sciences, 2021 Echinacea purpurea (EP) has been widely used to treat upper respiratory infections, influenza, and the common cold. It can also exert various pharmacological activities, such as anti-inflammatory and anti-allergic effects. However, the potential of EP to
Ha-Rim Kim +5 more
doaj +1 more source
Anti-CD70-IFN-γ immunocytokines are cytotoxic to RCC cell lines in the presence of bortezomib.
, 2013 RCC cell lines RenCa (A) or Caki-1 (B) were treated either with unfused anti-CD70 antibody (‘Anti-CD70’), with recombinant, native human or murine IFN-γ (‘Native’), or with human or murine IFN-γ immunocytokines (‘Anti-CD70 fusion’) for 72 h in the ...
Peirong Chen (403320) +7 more
core +1 more source
Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice. [PDF]
PLoS ONE, 2013 Mesothelin is a glycosylphosphatidylinositol-anchored glycoprotein that is highly expressed on the cell surface of malignant mesothelioma. Monoclonal antibodies against mesothelin are being evaluated for the treatment of mesothelioma.
Heungnam Kim, Wei Gao, Mitchell Ho
doaj +1 more source